Get the Stockscreener App
156.39
0.08%
-0.12
After Hours:
156.39
Glaukos Corporation stock is traded at $156.39, with a volume of 520.94K.
It is down -0.08% in the last 24 hours and up +6.86% over the past month.
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
See More
Previous Close:
$156.51
Open:
$157.24
24h Volume:
520.94K
Relative Volume:
0.92
Market Cap:
$8.59B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-52.83
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-0.09%
1M Performance:
+6.86%
6M Performance:
+25.96%
1Y Performance:
+74.99%
1-Day Range:
$153.68
$157.83
1-Week Range:
$142.71
$158.01
52-Week Range:
$83.90
$161.13
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
156.39 | 8.59B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Assenagon Asset Management S.A. Trims Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Oak Ridge Investments LLC Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Co. (NYSE:GKOS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Personal Finance - Business Wire
Glaukos Shares Rise Amid Promising Trial Results - TipRanks
GKOS Stock Gains Following Positive Study Data on iDose Platform - MSN
(GKOS) Trading Signals - Stock Traders Daily
Glaukos reports sustained efficacy in iDose TR trials By Investing.com - Investing.com South Africa
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform - BioSpace
Glaukos reports sustained efficacy in iDose TR trials - Investing.com
Glaukos Highlights Advances in Glaucoma Treatments - TipRanks
Glaukos says iDose TR showed sustained substantial IOP reductions in Phase 3 - TipRanks
Glaukos iDose TR Shows Strong 36-Month Results with 70% Patient Control Rate in Glaucoma Trial - StockTitan
Thomas Burns: The 2-Decade Bet That’s Paying Off - Orange County Business Journal
Here's Why You Should Add Glaukos Stock to Your Portfolio Now - MSN
Harbor Capital Advisors Inc. Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally? - MSN
Glaukos stock soars to all-time high of $153.72 By Investing.com - Investing.com Nigeria
Glaukos (NYSE:GKOS) Hits New 1-Year HighStill a Buy? - MarketBeat
Glaukos stock soars to all-time high of $153.72 - Investing.com
(GKOS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Glaukos price target raised to $157 from $149 at BTIG - Yahoo Finance
What 11 Analyst Ratings Have To Say About Glaukos - Benzinga
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday - Benzinga
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Stifel backs Glaukos shares with higher price target and positive long-term iDose outlook - Investing.com Canada
Glaukos Corporation Sees A Bright Future In Huntsville - Huntsville Business Journal
Franklin Resources Inc. Purchases 6,948 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA - MSN
GKOS (Glaukos) Change In Working Capital : $-36.3 Mil (TTM As of Sep. 2024) - GuruFocus.com
(GKOS)Analyzing Glaukos's Short Interest - Benzinga
(GKOS) Trading Report - Stock Traders Daily
Are Investors Undervaluing Glaukos Corporation (NYSE:GKOS) By 50%? - Simply Wall St
Glaukos (NYSE:GKOS) Reaches New 1-Year HighTime to Buy? - MarketBeat
Pharmaceutical giant chooses to invest $82 million in Huntsville facility - MSN
Glaukos Co. (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos president sells $498,715 in stock - Investing.com India
Glaukos director Gilbert H. Kliman sells shares worth $1.5 million - Investing.com India
Glaukos director Gilbert H. Kliman sells shares worth $1.5 million By Investing.com - Investing.com Australia
Glaukos president sells $498,715 in stock By Investing.com - Investing.com Australia
Glaukos Co. (NYSE:GKOS) Shares Sold by Principal Financial Group Inc. - MarketBeat
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):